Co-injection of ETV-2 and HGF viral vectors significantly improve angiogenesis in mice with hindlimb ischemia

Main Article Content

Phuc Van Pham Ngoc Bich Vu Thuy Thi-Thanh Dao Ha Thi-Ngan Le Lan Thi Phi Ngoc Kim Phan

Abstract

Introduction: Both ETV-2 and HGF factors are known to be important factors which trigger neo-angiogenesis both in vitro and in vivo models. This study aimed to treat hindlimb ischemia in mice by co-injection of ETV-2 and HGF viral vectors.


Methods: ETV-2 and HGF vectors were prepared per previous publications. The mouse ischemic hindlimb model was performed by ligating and burning the artery at the hindlimb. ETV-2 and HGF viral vectors were co-injected into the ligated and burnt sites.


Results: The results showed that co-injection of the vectors significantly improved angiogenesis as well as reduced leg loss in mice compared to placebo treatment. The percentage of mice who succumbed to ischemia was also significantly reduced compared to control.


Conclusion: Overall, this study suggests a potential impact of combining ETV-2 and HGF to treat angiogenesis. Use of ETV-2 and HGF viral vectors can be a promising therapy for ischemia treatment in the future.

Downloads

Download data is not yet available.

Article Details

How to Cite
PHAM, Phuc Van et al. Co-injection of ETV-2 and HGF viral vectors significantly improve angiogenesis in mice with hindlimb ischemia. Progress in Stem Cell, [S.l.], v. 4, n. 01, p. 189-200, july 2017. ISSN 2199-4633. Available at: <http://www.cellstemcell.org/index.php/PSC/article/view/193>. Date accessed: 18 aug. 2017. doi: https://doi.org/10.15419/psc.v4i01.193.
Section
Research Articles